<?xml version="1.0" encoding="UTF-8"?>
<drug type="small molecule" created="2008-03-19" updated="2019-12-02">
  <drugbank-id primary="true">DB06608</drugbank-id>
  <name>Tafenoquine</name>
  <description>Tafenoquine is an 8-aminoquinoline analogue of primaquine which varies only on the presence of a 5-phenoxy group.[A35671, A35690] It was discovered by the scientists at the Walter Reed Army Institute of Research in 1978 as a substitute for primaquine that would be more effective against relapsing vivax malaria.[A35690] Tafenoquine was further developed collaboratively between GlaxoSmithKline and Medicines for Malaria Venture.[A35677] It was FDA approved on July 20, 2018.[L3770]</description>
  <cas-number>106635-80-7</cas-number>
  <unii>262P8GS9L9</unii>
  <average-mass>463.501</average-mass>
  <monoisotopic-mass>463.208276263</monoisotopic-mass>
  <state>solid</state>
  <groups>
    <group>approved</group>
    <group>investigational</group>
  </groups>
  <general-references>
    <articles>
      <article>
        <ref-id>A35671</ref-id>
        <pubmed-id>25921416</pubmed-id>
        <citation>Rajapakse S, Rodrigo C, Fernando SD: Tafenoquine for preventing relapse in people with Plasmodium vivax malaria. Cochrane Database Syst Rev. 2015 Apr 29;(4):CD010458. doi: 10.1002/14651858.CD010458.pub2.</citation>
      </article>
      <article>
        <ref-id>A35677</ref-id>
        <pubmed-id>27528800</pubmed-id>
        <citation>Ebstie YA, Abay SM, Tadesse WT, Ejigu DA: Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date. Drug Des Devel Ther. 2016 Jul 26;10:2387-99. doi: 10.2147/DDDT.S61443. eCollection 2016.</citation>
      </article>
      <article>
        <ref-id>A35690</ref-id>
        <pubmed-id>10615272</pubmed-id>
        <citation>Peters W: The evolution of tafenoquine--antimalarial for a new millennium? J R Soc Med. 1999 Jul;92(7):345-52.</citation>
      </article>
      <article>
        <ref-id>A35693</ref-id>
        <pubmed-id>25759576</pubmed-id>
        <citation>Melariri P, Kalombo L, Nkuna P, Dube A, Hayeshi R, Ogutu B, Gibhard L, deKock C, Smith P, Wiesner L, Swai H: Oral lipid-based nanoformulation of tafenoquine enhanced bioavailability and blood stage antimalarial efficacy and led to a reduction in human red blood cell loss in mice. Int J Nanomedicine. 2015 Feb 20;10:1493-503. doi: 10.2147/IJN.S76317. eCollection 2015.</citation>
      </article>
    </articles>
    <textbooks>
      <textbook>
        <ref-id>T304</ref-id>
        <isbn/>
        <citation>Grayson L., Cosgrove S., Crowe S., Hope W., McCarthy J., Mills J., Mouton J., Paterson D. (2017). Kucer's the use of antibiotics (7th ed.). CRC Press LLc.</citation>
      </textbook>
    </textbooks>
    <links>
      <link>
        <ref-id>L3770</ref-id>
        <title>FDA approval</title>
        <url>https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&amp;varApplNo=210795</url>
      </link>
    </links>
    <attachments/>
  </general-references>
  <synthesis-reference/>
  <indication>Tafenoquine is used for the treatment and prevention of relapse of Vivax malaria in patients 16 years and older. Tafenoquine is not indicated to treat acute vivax malaria.[A35671] &#13;
&#13;
Malaria is a disease that remains to occur in many tropical countries. Vivax malaria, caused by _Plasmodium vivax_, is known to be less virulent and seldom causes death. However, it causes a substantive illness-related burden in endemic areas and it is known to present dormant forms in the hepatocytes named hypnozoites which can remain dormant for weeks or even months. This dormant form produces ongoing relapses.[A35671]</indication>
  <pharmacodynamics>In vitro studies have shown that tafenoquine presents an average 50% inhibitory concentration of 0.436 mcg against blood stages of seven strains of _P. falciparum_. In chloroquine-resistant _P. falciparum_ strains the IC50 of tafenoquine was greater when compared with primaquine and it ranged from 0.5 to 33.1 mcg. In studies evaluating the transmission-blocking activity of tafenoquine against the sporogonic stage of _P. vivax_, it was showed a reduced transmission at doses higher than 25 mg/kg.[A35677]&#13;
&#13;
In clinical trials, it was reported a tafenoquine-induced relapse prevention of 91.9% in cases of vivax malaria when pretreated with chloroquine. In prophylactic studies, tafenoquine showed an efficacy range from 84 to 87% against falciparum malaria and 99.1% against vivax malaria.[A35677]</pharmacodynamics>
  <mechanism-of-action>The mechanism of action of tafenoquine is not well established but studies have reported a longer and more effective action when compared to primaquine.[A35671] The active moiety of tafenoquine, 5,6 ortho quinone tafenoquine, seems to be redox cycled by _P. falciparum_ which are upregulated in gametocytes and liver stages. Once inside, the oxidated metabolite produces hydrogen peroxide and hydroxyl radicals. It is thought that these radicals produce leads to the parasite death.[A35677]&#13;
&#13;
On the other hand, tafenoquine inhibits heme polymerase in blood stage of parasites which explains the activity against blood stages of parasites.[A35677]</mechanism-of-action>
  <toxicity>Tafenoquine can cause hemolysis in people with glucose-6-phosphate dehydrogenase deficiency.[A35671] In preclinical studies, renal cell adenomas and carcinomas are increased in male rats with an overdose administration. However, this drug does not seem to be carcinogenic in humans and it was shown to lack mutagenic potential. In fertility studies, tafenoquine resulted in a reduced number of viable fetuses, implantation sites and corpora lutea.[FDA label]</toxicity>
  <metabolism>The activation of tafenoquine needs the activity of CYP 2D6 liver microsomal enzyme. This activation step produces the metabolite 5,6 ortho quinone tafenoquine. This metabolite is internalized by the parasite and reduced to radicals by ferredoxin-NADP+ reductase and diflavin reductase enzymes.[A35677] In the human, tafenoquine is metabolized by several metabolic pathways including O-demethylation, N-dealkylation, N-oxidation and oxidative deamination as well as C-hydroxylation of the 8-aminoalkylamino side chain.[T304]</metabolism>
  <absorption>The first-in-human pharmacokinetic study showed a tmax of 13.8 hours and this study suggested that the prolonged absorption from the gut can be due to absorption in the distal gastrointestinal tract combined with a slow clearance. The AUC and Cmax demonstrated an intersubject variability. The bioavailability of tafenoquine is increased in the presence of a high-fat meal by modifying the amount of drug absorbed rather than the rate of absorption. Once absorbed, the concentration of tafenoquine in the whole body is two-fold higher than the corresponding concentration in plasma and it seems to be highly distributed in the liver showing an AUC of approximately 80 times more than what is found in the plasma.[A35677]</absorption>
  <half-life>Tafenoquine presents a long half-life of approximately 14 days.[A35693]</half-life>
  <protein-binding>The plasma protein binding of tafenoquine in humans is very high and it represents about 99.5%.[T304]</protein-binding>
  <route-of-elimination>After degradation by different metabolic pathways, tafenoquine is slowly excreted from the body primarily in the feces and renal elimination of the unchanged form is very low.[T304]</route-of-elimination>
  <volume-of-distribution>Tafenoquine presents a high volume of distribution of approximately 2 560 L.[A35677]</volume-of-distribution>
  <clearance>Tafenoquine presents a low clearance of approximately 6 L/h.[A35677]</clearance>
  <salts>
    <salt>
      <drugbank-id primary="true">DBSALT002809</drugbank-id>
      <name>Tafenoquine succinate</name>
      <unii>DL5J0B8VSS</unii>
      <cas-number>106635-81-8</cas-number>
      <inchikey>CQBKFGJRAOXYIP-UHFFFAOYSA-N</inchikey>
      <average-mass>581.589</average-mass>
      <monoisotopic-mass>581.234884936</monoisotopic-mass>
    </salt>
  </salts>
  <synonyms>
    <synonym language="english" coder="inn/usan">Tafenoquine</synonym>
  </synonyms>
  <products>
    <product>
      <name>Arakoda</name>
      <labeller>60 Degrees Pharmaceuticals, LLC</labeller>
      <ndc-id/>
      <ndc-product-code>71475-257</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2018-08-20</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>100 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA210607</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
    <product>
      <name>Krintafel</name>
      <labeller>GlaxoSmithKline LLC</labeller>
      <ndc-id/>
      <ndc-product-code>0173-0889</ndc-product-code>
      <dpd-id/>
      <ema-product-code/>
      <ema-ma-number/>
      <started-marketing-on>2019-01-22</started-marketing-on>
      <ended-marketing-on/>
      <dosage-form>Tablet, film coated</dosage-form>
      <strength>150 mg/1</strength>
      <route>Oral</route>
      <fda-application-number>NDA210795</fda-application-number>
      <generic>false</generic>
      <over-the-counter>false</over-the-counter>
      <approved>true</approved>
      <country>US</country>
      <source>FDA NDC</source>
    </product>
  </products>
  <international-brands/>
  <mixtures>
    <mixture>
      <name>Arakoda</name>
      <ingredients>Tafenoquine</ingredients>
    </mixture>
    <mixture>
      <name>Krintafel</name>
      <ingredients>Tafenoquine</ingredients>
    </mixture>
  </mixtures>
  <packagers/>
  <manufacturers/>
  <prices/>
  <categories>
    <category>
      <category>Aminoquinolines</category>
      <mesh-id>D000634</mesh-id>
    </category>
    <category>
      <category>Anti-Infective Agents</category>
      <mesh-id>D000890</mesh-id>
    </category>
    <category>
      <category>Antimalarials</category>
      <mesh-id>D000962</mesh-id>
    </category>
    <category>
      <category>Antiparasitic Agents</category>
      <mesh-id>D000977</mesh-id>
    </category>
    <category>
      <category>Antiprotozoals</category>
      <mesh-id>D000981</mesh-id>
    </category>
    <category>
      <category>Cytochrome P-450 CYP2D6 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Cytochrome P-450 Substrates</category>
      <mesh-id/>
    </category>
    <category>
      <category>Heterocyclic Compounds, Fused-Ring</category>
      <mesh-id>D000072471</mesh-id>
    </category>
    <category>
      <category>MATE 1 Inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>MATE 2 Inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>MATE inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>OCT2 Inhibitors</category>
      <mesh-id/>
    </category>
    <category>
      <category>Quinolines</category>
      <mesh-id>D011804</mesh-id>
    </category>
  </categories>
  <affected-organisms>
    <affected-organism>Plasmodium</affected-organism>
  </affected-organisms>
  <dosages>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>100 mg/1</strength>
    </dosage>
    <dosage>
      <form>Tablet, film coated</form>
      <route>Oral</route>
      <strength>150 mg/1</strength>
    </dosage>
  </dosages>
  <atc-codes/>
  <ahfs-codes/>
  <pdb-entries/>
  <fda-label>//s3-us-west-2.amazonaws.com/drugbank/fda_labels/DB06608.pdf?1532370524</fda-label>
  <msds>//s3-us-west-2.amazonaws.com/drugbank/msds/DB06608.pdf?1532371323</msds>
  <patents>
    <patent>
      <number>10342791</number>
      <country>United States</country>
      <approved>2019-07-09</approved>
      <expires>2035-12-02</expires>
      <pediatric-extension>false</pediatric-extension>
    </patent>
  </patents>
  <food-interactions/>
  <drug-interactions>
    <drug-interaction>
      <drugbank-id>DB06697</drugbank-id>
      <name>Artemether</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Artemether.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06708</drugbank-id>
      <name>Lumefantrine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Lumefantrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00358</drugbank-id>
      <name>Mefloquine</name>
      <description>The risk or severity of adverse effects can be increased when Tafenoquine is combined with Mefloquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00372</drugbank-id>
      <name>Thiethylperazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Thiethylperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00420</drugbank-id>
      <name>Promazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Promazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00433</drugbank-id>
      <name>Prochlorperazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Prochlorperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00508</drugbank-id>
      <name>Triflupromazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Triflupromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00623</drugbank-id>
      <name>Fluphenazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Fluphenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00679</drugbank-id>
      <name>Thioridazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Thioridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00680</drugbank-id>
      <name>Moricizine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Moricizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00831</drugbank-id>
      <name>Trifluoperazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Trifluoperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00850</drugbank-id>
      <name>Perphenazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Perphenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00933</drugbank-id>
      <name>Mesoridazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Mesoridazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01063</drugbank-id>
      <name>Acetophenazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Acetophenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01069</drugbank-id>
      <name>Promethazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Promethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01246</drugbank-id>
      <name>Alimemazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Alimemazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01403</drugbank-id>
      <name>Methotrimeprazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Methotrimeprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01608</drugbank-id>
      <name>Periciazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Periciazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01614</drugbank-id>
      <name>Acepromazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Acepromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01615</drugbank-id>
      <name>Aceprometazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Aceprometazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01621</drugbank-id>
      <name>Pipotiazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Pipotiazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01622</drugbank-id>
      <name>Thioproperazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Thioproperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05687</drugbank-id>
      <name>BL-1020</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with BL-1020.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09000</drugbank-id>
      <name>Cyamemazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Cyamemazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09241</drugbank-id>
      <name>Methylene blue</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Methylene blue.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11540</drugbank-id>
      <name>Propiopromazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Propiopromazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12710</drugbank-id>
      <name>Perazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Perazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13213</drugbank-id>
      <name>Butaperazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Butaperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13382</drugbank-id>
      <name>Chlorproethazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Chlorproethazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13420</drugbank-id>
      <name>Thiazinam</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Thiazinam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13784</drugbank-id>
      <name>Dixyrazine</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Dixyrazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14651</drugbank-id>
      <name>Perphenazine enanthate</name>
      <description>The risk or severity of QTc prolongation can be increased when Tafenoquine is combined with Perphenazine enanthate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00250</drugbank-id>
      <name>Dapsone</name>
      <description>The risk or severity of adverse effects can be increased when Tafenoquine is combined with Dapsone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00390</drugbank-id>
      <name>Digoxin</name>
      <description>The serum concentration of Digoxin can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00511</drugbank-id>
      <name>Acetyldigitoxin</name>
      <description>The serum concentration of Acetyldigitoxin can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01078</drugbank-id>
      <name>Deslanoside</name>
      <description>The serum concentration of Deslanoside can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01092</drugbank-id>
      <name>Ouabain</name>
      <description>The serum concentration of Ouabain can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01396</drugbank-id>
      <name>Digitoxin</name>
      <description>The serum concentration of Digitoxin can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12843</drugbank-id>
      <name>Oleandrin</name>
      <description>The serum concentration of Oleandrin can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13240</drugbank-id>
      <name>Cymarin</name>
      <description>The serum concentration of Cymarin can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13307</drugbank-id>
      <name>Proscillaridin</name>
      <description>The serum concentration of Proscillaridin can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13401</drugbank-id>
      <name>Metildigoxin</name>
      <description>The serum concentration of Metildigoxin can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13467</drugbank-id>
      <name>Lanatoside C</name>
      <description>The serum concentration of Lanatoside C can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13537</drugbank-id>
      <name>Gitoformate</name>
      <description>The serum concentration of Gitoformate can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13691</drugbank-id>
      <name>Acetyldigoxin</name>
      <description>The serum concentration of Acetyldigoxin can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13756</drugbank-id>
      <name>Peruvoside</name>
      <description>The serum concentration of Peruvoside can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08881</drugbank-id>
      <name>Vemurafenib</name>
      <description>The risk or severity of QTc prolongation can be increased when Vemurafenib is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00536</drugbank-id>
      <name>Guanidine</name>
      <description>The excretion of Guanidine can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01030</drugbank-id>
      <name>Topotecan</name>
      <description>The excretion of Topotecan can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12001</drugbank-id>
      <name>Abemaciclib</name>
      <description>The excretion of Abemaciclib can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11817</drugbank-id>
      <name>Baricitinib</name>
      <description>The excretion of Baricitinib can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00537</drugbank-id>
      <name>Ciprofloxacin</name>
      <description>The excretion of Ciprofloxacin can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00567</drugbank-id>
      <name>Cephalexin</name>
      <description>The excretion of Cephalexin can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00787</drugbank-id>
      <name>Acyclovir</name>
      <description>The excretion of Acyclovir can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01004</drugbank-id>
      <name>Ganciclovir</name>
      <description>The excretion of Ganciclovir can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01137</drugbank-id>
      <name>Levofloxacin</name>
      <description>The excretion of Levofloxacin can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01333</drugbank-id>
      <name>Cefradine</name>
      <description>The excretion of Cefradine can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04574</drugbank-id>
      <name>Estrone sulfate</name>
      <description>The excretion of Estrone sulfate can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08840</drugbank-id>
      <name>N-methylnicotinamide</name>
      <description>The excretion of N-methylnicotinamide can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12377</drugbank-id>
      <name>Relebactam</name>
      <description>The excretion of Relebactam can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01203</drugbank-id>
      <name>Nadolol</name>
      <description>The excretion of Tafenoquine can be decreased when combined with Nadolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00879</drugbank-id>
      <name>Emtricitabine</name>
      <description>The excretion of Emtricitabine can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00477</drugbank-id>
      <name>Chlorpromazine</name>
      <description>The metabolism of Chlorpromazine can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00501</drugbank-id>
      <name>Cimetidine</name>
      <description>The metabolism of Cimetidine can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00091</drugbank-id>
      <name>Cyclosporine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Cyclosporine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00169</drugbank-id>
      <name>Cholecalciferol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Cholecalciferol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00176</drugbank-id>
      <name>Fluvoxamine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Fluvoxamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00264</drugbank-id>
      <name>Metoprolol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Metoprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00285</drugbank-id>
      <name>Venlafaxine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Venlafaxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00342</drugbank-id>
      <name>Terfenadine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Terfenadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00349</drugbank-id>
      <name>Clobazam</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Clobazam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00363</drugbank-id>
      <name>Clozapine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Clozapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00468</drugbank-id>
      <name>Quinine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Quinine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00476</drugbank-id>
      <name>Duloxetine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Duloxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00482</drugbank-id>
      <name>Celecoxib</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Celecoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00496</drugbank-id>
      <name>Darifenacin</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Darifenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00503</drugbank-id>
      <name>Ritonavir</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Ritonavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00608</drugbank-id>
      <name>Chloroquine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Chloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00705</drugbank-id>
      <name>Delavirdine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Delavirdine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00752</drugbank-id>
      <name>Tranylcypromine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Tranylcypromine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00857</drugbank-id>
      <name>Terbinafine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Terbinafine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00932</drugbank-id>
      <name>Tipranavir</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Tipranavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01026</drugbank-id>
      <name>Ketoconazole</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Ketoconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01074</drugbank-id>
      <name>Perhexiline</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Perhexiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01079</drugbank-id>
      <name>Tegaserod</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Tegaserod.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01601</drugbank-id>
      <name>Lopinavir</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Lopinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB02703</drugbank-id>
      <name>Fusidic acid</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Fusidic acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04868</drugbank-id>
      <name>Nilotinib</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Nilotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05812</drugbank-id>
      <name>Abiraterone</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Abiraterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06603</drugbank-id>
      <name>Panobinostat</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Panobinostat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06684</drugbank-id>
      <name>Vilazodone</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Vilazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06729</drugbank-id>
      <name>Sulfaphenazole</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Sulfaphenazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06819</drugbank-id>
      <name>Phenylbutyric acid</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Phenylbutyric acid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08816</drugbank-id>
      <name>Ticagrelor</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Ticagrelor.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09238</drugbank-id>
      <name>Manidipine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Manidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09291</drugbank-id>
      <name>Rolapitant</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Rolapitant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11586</drugbank-id>
      <name>Asunaprevir</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Asunaprevir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11642</drugbank-id>
      <name>Pitolisant</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Pitolisant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11672</drugbank-id>
      <name>Curcumin</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Curcumin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12332</drugbank-id>
      <name>Rucaparib</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Rucaparib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12693</drugbank-id>
      <name>Ritanserin</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Ritanserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13174</drugbank-id>
      <name>Rhein</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Rhein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01087</drugbank-id>
      <name>Primaquine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Primaquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00458</drugbank-id>
      <name>Imipramine</name>
      <description>The metabolism of Imipramine can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01151</drugbank-id>
      <name>Desipramine</name>
      <description>The metabolism of Desipramine can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09167</drugbank-id>
      <name>Dosulepin</name>
      <description>The metabolism of Dosulepin can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00243</drugbank-id>
      <name>Ranolazine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Ranolazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04871</drugbank-id>
      <name>Lorcaserin</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Lorcaserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08893</drugbank-id>
      <name>Mirabegron</name>
      <description>The metabolism of Mirabegron can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00622</drugbank-id>
      <name>Nicardipine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Nicardipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00472</drugbank-id>
      <name>Fluoxetine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Fluoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00604</drugbank-id>
      <name>Cisapride</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Cisapride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00715</drugbank-id>
      <name>Paroxetine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Paroxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00908</drugbank-id>
      <name>Quinidine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Quinidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01012</drugbank-id>
      <name>Cinacalcet</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Cinacalcet.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01156</drugbank-id>
      <name>Bupropion</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Bupropion.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01173</drugbank-id>
      <name>Orphenadrine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Orphenadrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01182</drugbank-id>
      <name>Propafenone</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Propafenone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01218</drugbank-id>
      <name>Halofantrine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Halofantrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06595</drugbank-id>
      <name>Midostaurin</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Midostaurin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08909</drugbank-id>
      <name>Glycerol phenylbutyrate</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Glycerol phenylbutyrate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11963</drugbank-id>
      <name>Dacomitinib</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Dacomitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01273</drugbank-id>
      <name>Varenicline</name>
      <description>The excretion of Varenicline can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00457</drugbank-id>
      <name>Prazosin</name>
      <description>The serum concentration of Prazosin can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14754</drugbank-id>
      <name>Solriamfetol</name>
      <description>The serum concentration of Solriamfetol can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00863</drugbank-id>
      <name>Ranitidine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Ranitidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00208</drugbank-id>
      <name>Ticlopidine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Ticlopidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00215</drugbank-id>
      <name>Citalopram</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Citalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00281</drugbank-id>
      <name>Lidocaine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Lidocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00283</drugbank-id>
      <name>Clemastine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Clemastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00333</drugbank-id>
      <name>Methadone</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Methadone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00398</drugbank-id>
      <name>Sorafenib</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Sorafenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00412</drugbank-id>
      <name>Rosiglitazone</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Rosiglitazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00439</drugbank-id>
      <name>Cerivastatin</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Cerivastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00502</drugbank-id>
      <name>Haloperidol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Haloperidol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00557</drugbank-id>
      <name>Hydroxyzine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Hydroxyzine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00574</drugbank-id>
      <name>Fenfluramine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Fenfluramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00598</drugbank-id>
      <name>Labetalol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Labetalol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00633</drugbank-id>
      <name>Dexmedetomidine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Dexmedetomidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00647</drugbank-id>
      <name>Dextropropoxyphene</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Dextropropoxyphene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00656</drugbank-id>
      <name>Trazodone</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Trazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00675</drugbank-id>
      <name>Tamoxifen</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Tamoxifen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00780</drugbank-id>
      <name>Phenelzine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Phenelzine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00792</drugbank-id>
      <name>Tripelennamine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Tripelennamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00810</drugbank-id>
      <name>Biperiden</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Biperiden.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00834</drugbank-id>
      <name>Mifepristone</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Mifepristone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00907</drugbank-id>
      <name>Cocaine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Cocaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00997</drugbank-id>
      <name>Doxorubicin</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Doxorubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01005</drugbank-id>
      <name>Hydroxyurea</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Hydroxyurea.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01075</drugbank-id>
      <name>Diphenhydramine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Diphenhydramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01076</drugbank-id>
      <name>Atorvastatin</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Atorvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01110</drugbank-id>
      <name>Miconazole</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Miconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01114</drugbank-id>
      <name>Chlorpheniramine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Chlorpheniramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01128</drugbank-id>
      <name>Bicalutamide</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Bicalutamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01171</drugbank-id>
      <name>Moclobemide</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Moclobemide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01186</drugbank-id>
      <name>Pergolide</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Pergolide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01193</drugbank-id>
      <name>Acebutolol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Acebutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01233</drugbank-id>
      <name>Metoclopramide</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Metoclopramide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01388</drugbank-id>
      <name>Mibefradil</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Mibefradil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01580</drugbank-id>
      <name>Oxprenolol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Oxprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01611</drugbank-id>
      <name>Hydroxychloroquine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Hydroxychloroquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04818</drugbank-id>
      <name>Iproniazid</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Iproniazid.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04884</drugbank-id>
      <name>Dapoxetine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Dapoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05271</drugbank-id>
      <name>Rotigotine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Rotigotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06204</drugbank-id>
      <name>Tapentadol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Tapentadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06217</drugbank-id>
      <name>Vernakalant</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Vernakalant.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06370</drugbank-id>
      <name>Indisulam</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Indisulam.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06412</drugbank-id>
      <name>Oxymetholone</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Oxymetholone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06654</drugbank-id>
      <name>Safinamide</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Safinamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06727</drugbank-id>
      <name>Sparteine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Sparteine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08864</drugbank-id>
      <name>Rilpivirine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Rilpivirine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09049</drugbank-id>
      <name>Naloxegol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Naloxegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09078</drugbank-id>
      <name>Lenvatinib</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Lenvatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09118</drugbank-id>
      <name>Stiripentol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Stiripentol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09224</drugbank-id>
      <name>Melperone</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Melperone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09555</drugbank-id>
      <name>Dexchlorpheniramine maleate</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Dexchlorpheniramine maleate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11633</drugbank-id>
      <name>Isavuconazole</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Isavuconazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11638</drugbank-id>
      <name>Artenimol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Artenimol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11753</drugbank-id>
      <name>Rifamycin</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Rifamycin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11994</drugbank-id>
      <name>Diacerein</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Diacerein.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12245</drugbank-id>
      <name>Triclabendazole</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Triclabendazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12523</drugbank-id>
      <name>Mizolastine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Mizolastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13139</drugbank-id>
      <name>Levosalbutamol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Levosalbutamol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13679</drugbank-id>
      <name>Dexchlorpheniramine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Dexchlorpheniramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13874</drugbank-id>
      <name>Enasidenib</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Enasidenib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13975</drugbank-id>
      <name>Black cohosh</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Black cohosh.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00763</drugbank-id>
      <name>Methimazole</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Methimazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00972</drugbank-id>
      <name>Azelastine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Azelastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01023</drugbank-id>
      <name>Felodipine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Felodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01062</drugbank-id>
      <name>Oxybutynin</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Oxybutynin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01093</drugbank-id>
      <name>Dimethyl sulfoxide</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Dimethyl sulfoxide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04911</drugbank-id>
      <name>Oritavancin</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Oritavancin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01115</drugbank-id>
      <name>Nifedipine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Nifedipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01244</drugbank-id>
      <name>Bepridil</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Bepridil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00220</drugbank-id>
      <name>Nelfinavir</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Nelfinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06691</drugbank-id>
      <name>Mepyramine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Mepyramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01096</drugbank-id>
      <name>Oxamniquine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Oxamniquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00528</drugbank-id>
      <name>Lercanidipine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Lercanidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01562</drugbank-id>
      <name>1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with 1-(2-Phenylethyl)-4-phenyl-4-acetoxypiperidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09061</drugbank-id>
      <name>Cannabidiol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Cannabidiol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14009</drugbank-id>
      <name>Medical Cannabis</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Medical Cannabis.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14011</drugbank-id>
      <name>Nabiximols</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Nabiximols.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14635</drugbank-id>
      <name>Curcumin sulfate</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Curcumin sulfate.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09039</drugbank-id>
      <name>Eliglustat</name>
      <description>The metabolism of Eliglustat can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01590</drugbank-id>
      <name>Everolimus</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Everolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00627</drugbank-id>
      <name>Niacin</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Niacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00022</drugbank-id>
      <name>Peginterferon alfa-2b</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Peginterferon alfa-2b.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00209</drugbank-id>
      <name>Trospium</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Trospium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00227</drugbank-id>
      <name>Lovastatin</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Lovastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00234</drugbank-id>
      <name>Reboxetine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Reboxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00238</drugbank-id>
      <name>Nevirapine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Nevirapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00246</drugbank-id>
      <name>Ziprasidone</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Ziprasidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00317</drugbank-id>
      <name>Gefitinib</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Gefitinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00338</drugbank-id>
      <name>Omeprazole</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Omeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00361</drugbank-id>
      <name>Vinorelbine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Vinorelbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00381</drugbank-id>
      <name>Amlodipine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Amlodipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00448</drugbank-id>
      <name>Lansoprazole</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Lansoprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00494</drugbank-id>
      <name>Entacapone</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Entacapone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00570</drugbank-id>
      <name>Vinblastine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Vinblastine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00571</drugbank-id>
      <name>Propranolol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Propranolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00619</drugbank-id>
      <name>Imatinib</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Imatinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00661</drugbank-id>
      <name>Verapamil</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Verapamil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00734</drugbank-id>
      <name>Risperidone</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Risperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00921</drugbank-id>
      <name>Buprenorphine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Buprenorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00960</drugbank-id>
      <name>Pindolol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Pindolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01037</drugbank-id>
      <name>Selegiline</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Selegiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01129</drugbank-id>
      <name>Rabeprazole</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Rabeprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01131</drugbank-id>
      <name>Proguanil</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Proguanil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01149</drugbank-id>
      <name>Nefazodone</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Nefazodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01191</drugbank-id>
      <name>Dexfenfluramine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Dexfenfluramine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01206</drugbank-id>
      <name>Lomustine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Lomustine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01232</drugbank-id>
      <name>Saquinavir</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Saquinavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01255</drugbank-id>
      <name>Lisdexamfetamine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Lisdexamfetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01323</drugbank-id>
      <name>St. John's Wort</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with St. John's Wort.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01628</drugbank-id>
      <name>Etoricoxib</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Etoricoxib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04938</drugbank-id>
      <name>Ospemifene</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Ospemifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06287</drugbank-id>
      <name>Temsirolimus</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Temsirolimus.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06512</drugbank-id>
      <name>Deramciclane</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Deramciclane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06700</drugbank-id>
      <name>Desvenlafaxine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Desvenlafaxine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09065</drugbank-id>
      <name>Cobicistat</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Cobicistat.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01104</drugbank-id>
      <name>Sertraline</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Sertraline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00182</drugbank-id>
      <name>Amphetamine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Amphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00184</drugbank-id>
      <name>Nicotine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Nicotine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00185</drugbank-id>
      <name>Cevimeline</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Cevimeline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00187</drugbank-id>
      <name>Esmolol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Esmolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00188</drugbank-id>
      <name>Bortezomib</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Bortezomib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00193</drugbank-id>
      <name>Tramadol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Tramadol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00195</drugbank-id>
      <name>Betaxolol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Betaxolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00203</drugbank-id>
      <name>Sildenafil</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Sildenafil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00216</drugbank-id>
      <name>Eletriptan</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Eletriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00245</drugbank-id>
      <name>Benzatropine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Benzatropine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00289</drugbank-id>
      <name>Atomoxetine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Atomoxetine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00297</drugbank-id>
      <name>Bupivacaine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Bupivacaine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00316</drugbank-id>
      <name>Acetaminophen</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Acetaminophen.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00318</drugbank-id>
      <name>Codeine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Codeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00335</drugbank-id>
      <name>Atenolol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Atenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00343</drugbank-id>
      <name>Diltiazem</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Diltiazem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00356</drugbank-id>
      <name>Chlorzoxazone</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Chlorzoxazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00370</drugbank-id>
      <name>Mirtazapine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Mirtazapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00373</drugbank-id>
      <name>Timolol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Timolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00377</drugbank-id>
      <name>Palonosetron</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Palonosetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00379</drugbank-id>
      <name>Mexiletine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Mexiletine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00396</drugbank-id>
      <name>Progesterone</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Progesterone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00409</drugbank-id>
      <name>Remoxipride</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Remoxipride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00425</drugbank-id>
      <name>Zolpidem</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Zolpidem.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00490</drugbank-id>
      <name>Buspirone</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Buspirone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00497</drugbank-id>
      <name>Oxycodone</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Oxycodone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00514</drugbank-id>
      <name>Dextromethorphan</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Dextromethorphan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00530</drugbank-id>
      <name>Erlotinib</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Erlotinib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00568</drugbank-id>
      <name>Cinnarizine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Cinnarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00589</drugbank-id>
      <name>Lisuride</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Lisuride.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00590</drugbank-id>
      <name>Doxazosin</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Doxazosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00592</drugbank-id>
      <name>Piperazine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Piperazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00637</drugbank-id>
      <name>Astemizole</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Astemizole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00641</drugbank-id>
      <name>Simvastatin</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Simvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00674</drugbank-id>
      <name>Galantamine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Galantamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00699</drugbank-id>
      <name>Nicergoline</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Nicergoline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00701</drugbank-id>
      <name>Amprenavir</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Amprenavir.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00706</drugbank-id>
      <name>Tamsulosin</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Tamsulosin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00731</drugbank-id>
      <name>Nateglinide</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Nateglinide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00737</drugbank-id>
      <name>Meclizine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Meclizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00738</drugbank-id>
      <name>Pentamidine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Pentamidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00757</drugbank-id>
      <name>Dolasetron</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Dolasetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00805</drugbank-id>
      <name>Minaprine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Minaprine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00836</drugbank-id>
      <name>Loperamide</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Loperamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00843</drugbank-id>
      <name>Donepezil</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Donepezil.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00866</drugbank-id>
      <name>Alprenolol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Alprenolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00904</drugbank-id>
      <name>Ondansetron</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Ondansetron.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00914</drugbank-id>
      <name>Phenformin</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Phenformin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00918</drugbank-id>
      <name>Almotriptan</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Almotriptan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00934</drugbank-id>
      <name>Maprotiline</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Maprotiline.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00983</drugbank-id>
      <name>Formoterol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Formoterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01028</drugbank-id>
      <name>Methoxyflurane</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Methoxyflurane.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01036</drugbank-id>
      <name>Tolterodine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Tolterodine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01095</drugbank-id>
      <name>Fluvastatin</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Fluvastatin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01136</drugbank-id>
      <name>Carvedilol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Carvedilol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01166</drugbank-id>
      <name>Cilostazol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Cilostazol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01177</drugbank-id>
      <name>Idarubicin</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Idarubicin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01184</drugbank-id>
      <name>Domperidone</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Domperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01192</drugbank-id>
      <name>Oxymorphone</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Oxymorphone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01224</drugbank-id>
      <name>Quetiapine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Quetiapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01228</drugbank-id>
      <name>Encainide</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Encainide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01238</drugbank-id>
      <name>Aripiprazole</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Aripiprazole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01267</drugbank-id>
      <name>Paliperidone</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Paliperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01274</drugbank-id>
      <name>Arformoterol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Arformoterol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01295</drugbank-id>
      <name>Bevantolol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Bevantolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01297</drugbank-id>
      <name>Practolol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Practolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01359</drugbank-id>
      <name>Penbutolol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Penbutolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01392</drugbank-id>
      <name>Yohimbine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Yohimbine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01409</drugbank-id>
      <name>Tiotropium</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Tiotropium.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01424</drugbank-id>
      <name>Aminophenazone</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Aminophenazone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01429</drugbank-id>
      <name>Aprindine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Aprindine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01454</drugbank-id>
      <name>Midomafetamine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Midomafetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01466</drugbank-id>
      <name>Ethylmorphine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Ethylmorphine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01472</drugbank-id>
      <name>4-Methoxyamphetamine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with 4-Methoxyamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01551</drugbank-id>
      <name>Dihydrocodeine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Dihydrocodeine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01576</drugbank-id>
      <name>Dextroamphetamine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Dextroamphetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01577</drugbank-id>
      <name>Metamfetamine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Metamfetamine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01591</drugbank-id>
      <name>Solifenacin</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Solifenacin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01624</drugbank-id>
      <name>Zuclopenthixol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Zuclopenthixol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB03783</drugbank-id>
      <name>Phenacetin</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Phenacetin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04829</drugbank-id>
      <name>Lysergic acid diethylamide</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Lysergic acid diethylamide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04840</drugbank-id>
      <name>Debrisoquine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Debrisoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04841</drugbank-id>
      <name>Flunarizine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Flunarizine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04844</drugbank-id>
      <name>Tetrabenazine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Tetrabenazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04846</drugbank-id>
      <name>Celiprolol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Celiprolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04861</drugbank-id>
      <name>Nebivolol</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Nebivolol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04905</drugbank-id>
      <name>Tesmilifene</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Tesmilifene.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04920</drugbank-id>
      <name>Clevidipine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Clevidipine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04946</drugbank-id>
      <name>Iloperidone</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Iloperidone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04948</drugbank-id>
      <name>Lofexidine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Lofexidine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05109</drugbank-id>
      <name>Trabectedin</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Trabectedin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06016</drugbank-id>
      <name>Cariprazine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Cariprazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06144</drugbank-id>
      <name>Sertindole</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Sertindole.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06148</drugbank-id>
      <name>Mianserin</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Mianserin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06203</drugbank-id>
      <name>Alogliptin</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Alogliptin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06292</drugbank-id>
      <name>Dapagliflozin</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Dapagliflozin.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06506</drugbank-id>
      <name>Repinotan</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Repinotan.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06678</drugbank-id>
      <name>Esmirtazapine</name>
      <description>The metabolism of Esmirtazapine can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06702</drugbank-id>
      <name>Fesoterodine</name>
      <description>The metabolism of Fesoterodine can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06726</drugbank-id>
      <name>Bufuralol</name>
      <description>The metabolism of Bufuralol can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06735</drugbank-id>
      <name>Enclomiphene</name>
      <description>The metabolism of Enclomiphene can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06770</drugbank-id>
      <name>Benzyl alcohol</name>
      <description>The metabolism of Benzyl alcohol can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08807</drugbank-id>
      <name>Bopindolol</name>
      <description>The metabolism of Bopindolol can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08808</drugbank-id>
      <name>Bupranolol</name>
      <description>The metabolism of Bupranolol can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08901</drugbank-id>
      <name>Ponatinib</name>
      <description>The metabolism of Ponatinib can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08918</drugbank-id>
      <name>Levomilnacipran</name>
      <description>The metabolism of Levomilnacipran can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08922</drugbank-id>
      <name>Perospirone</name>
      <description>The metabolism of Perospirone can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08952</drugbank-id>
      <name>Indenolol</name>
      <description>The metabolism of Indenolol can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09013</drugbank-id>
      <name>Befunolol</name>
      <description>The metabolism of Befunolol can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09048</drugbank-id>
      <name>Netupitant</name>
      <description>The metabolism of Netupitant can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09053</drugbank-id>
      <name>Ibrutinib</name>
      <description>The metabolism of Ibrutinib can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09068</drugbank-id>
      <name>Vortioxetine</name>
      <description>The metabolism of Vortioxetine can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09076</drugbank-id>
      <name>Umeclidinium</name>
      <description>The metabolism of Umeclidinium can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09128</drugbank-id>
      <name>Brexpiprazole</name>
      <description>The metabolism of Brexpiprazole can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09183</drugbank-id>
      <name>Dasabuvir</name>
      <description>The metabolism of Dasabuvir can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09195</drugbank-id>
      <name>Lorpiprazole</name>
      <description>The metabolism of Lorpiprazole can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09204</drugbank-id>
      <name>Arotinolol</name>
      <description>The metabolism of Arotinolol can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09288</drugbank-id>
      <name>Propacetamol</name>
      <description>The metabolism of Propacetamol can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09351</drugbank-id>
      <name>Levobetaxolol</name>
      <description>The metabolism of Levobetaxolol can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09570</drugbank-id>
      <name>Ixazomib</name>
      <description>The metabolism of Ixazomib can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11130</drugbank-id>
      <name>Opium</name>
      <description>The metabolism of Opium can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11614</drugbank-id>
      <name>Rupatadine</name>
      <description>The metabolism of Rupatadine can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11718</drugbank-id>
      <name>Encorafenib</name>
      <description>The metabolism of Encorafenib can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11770</drugbank-id>
      <name>Talinolol</name>
      <description>The metabolism of Talinolol can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11785</drugbank-id>
      <name>Anisodamine</name>
      <description>The metabolism of Anisodamine can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11855</drugbank-id>
      <name>Revefenacin</name>
      <description>The metabolism of Revefenacin can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11915</drugbank-id>
      <name>Valbenazine</name>
      <description>The metabolism of Valbenazine can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11979</drugbank-id>
      <name>Elagolix</name>
      <description>The metabolism of Elagolix can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12070</drugbank-id>
      <name>Letermovir</name>
      <description>The metabolism of Letermovir can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12161</drugbank-id>
      <name>Deutetrabenazine</name>
      <description>The metabolism of Deutetrabenazine can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12212</drugbank-id>
      <name>Landiolol</name>
      <description>The metabolism of Landiolol can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12752</drugbank-id>
      <name>Bucindolol</name>
      <description>The metabolism of Bucindolol can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13293</drugbank-id>
      <name>Ipecac</name>
      <description>The metabolism of Ipecac can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13443</drugbank-id>
      <name>Esatenolol</name>
      <description>The metabolism of Esatenolol can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13508</drugbank-id>
      <name>Cloranolol</name>
      <description>The metabolism of Cloranolol can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13530</drugbank-id>
      <name>Mepindolol</name>
      <description>The metabolism of Mepindolol can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13757</drugbank-id>
      <name>Epanolol</name>
      <description>The metabolism of Epanolol can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB13775</drugbank-id>
      <name>Tertatolol</name>
      <description>The metabolism of Tertatolol can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14185</drugbank-id>
      <name>Aripiprazole lauroxil</name>
      <description>The metabolism of Aripiprazole lauroxil can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09173</drugbank-id>
      <name>Butyrfentanyl</name>
      <description>The metabolism of Butyrfentanyl can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB11757</drugbank-id>
      <name>Istradefylline</name>
      <description>The metabolism of Istradefylline can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00334</drugbank-id>
      <name>Olanzapine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Olanzapine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01071</drugbank-id>
      <name>Mequitazine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Mequitazine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01410</drugbank-id>
      <name>Ciclesonide</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Ciclesonide.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04889</drugbank-id>
      <name>Bicifadine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Bicifadine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14010</drugbank-id>
      <name>5-methoxy-N,N-dimethyltryptamine</name>
      <description>The metabolism of 5-methoxy-N,N-dimethyltryptamine can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06589</drugbank-id>
      <name>Pazopanib</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Pazopanib.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01435</drugbank-id>
      <name>Antipyrine</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Antipyrine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00277</drugbank-id>
      <name>Theophylline</name>
      <description>The metabolism of Theophylline can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00321</drugbank-id>
      <name>Amitriptyline</name>
      <description>The metabolism of Amitriptyline can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00344</drugbank-id>
      <name>Protriptyline</name>
      <description>The metabolism of Protriptyline can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00454</drugbank-id>
      <name>Meperidine</name>
      <description>The metabolism of Meperidine can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00489</drugbank-id>
      <name>Sotalol</name>
      <description>The metabolism of Sotalol can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00532</drugbank-id>
      <name>Mephenytoin</name>
      <description>The metabolism of Mephenytoin can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00540</drugbank-id>
      <name>Nortriptyline</name>
      <description>The metabolism of Nortriptyline can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00543</drugbank-id>
      <name>Amoxapine</name>
      <description>The metabolism of Amoxapine can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00575</drugbank-id>
      <name>Clonidine</name>
      <description>The metabolism of Clonidine can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00726</drugbank-id>
      <name>Trimipramine</name>
      <description>The metabolism of Trimipramine can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01035</drugbank-id>
      <name>Procainamide</name>
      <description>The metabolism of Procainamide can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01100</drugbank-id>
      <name>Pimozide</name>
      <description>The metabolism of Pimozide can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01118</drugbank-id>
      <name>Amiodarone</name>
      <description>The metabolism of Amiodarone can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01142</drugbank-id>
      <name>Doxepin</name>
      <description>The metabolism of Doxepin can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01195</drugbank-id>
      <name>Flecainide</name>
      <description>The metabolism of Flecainide can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01242</drugbank-id>
      <name>Clomipramine</name>
      <description>The metabolism of Clomipramine can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12930</drugbank-id>
      <name>Opipramol</name>
      <description>The metabolism of Opipramol can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00005</drugbank-id>
      <name>Etanercept</name>
      <description>The metabolism of Tafenoquine can be increased when combined with Etanercept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00026</drugbank-id>
      <name>Anakinra</name>
      <description>The metabolism of Tafenoquine can be increased when combined with Anakinra.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00051</drugbank-id>
      <name>Adalimumab</name>
      <description>The metabolism of Tafenoquine can be increased when combined with Adalimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00065</drugbank-id>
      <name>Infliximab</name>
      <description>The metabolism of Tafenoquine can be increased when combined with Infliximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01281</drugbank-id>
      <name>Abatacept</name>
      <description>The metabolism of Tafenoquine can be increased when combined with Abatacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04956</drugbank-id>
      <name>Afelimomab</name>
      <description>The metabolism of Tafenoquine can be increased when combined with Afelimomab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05676</drugbank-id>
      <name>Apremilast</name>
      <description>The metabolism of Tafenoquine can be increased when combined with Apremilast.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06168</drugbank-id>
      <name>Canakinumab</name>
      <description>The metabolism of Tafenoquine can be increased when combined with Canakinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06273</drugbank-id>
      <name>Tocilizumab</name>
      <description>The metabolism of Tafenoquine can be increased when combined with Tocilizumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06372</drugbank-id>
      <name>Rilonacept</name>
      <description>The metabolism of Tafenoquine can be increased when combined with Rilonacept.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06674</drugbank-id>
      <name>Golimumab</name>
      <description>The metabolism of Tafenoquine can be increased when combined with Golimumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08904</drugbank-id>
      <name>Certolizumab pegol</name>
      <description>The metabolism of Tafenoquine can be increased when combined with Certolizumab pegol.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09029</drugbank-id>
      <name>Secukinumab</name>
      <description>The metabolism of Tafenoquine can be increased when combined with Secukinumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09036</drugbank-id>
      <name>Siltuximab</name>
      <description>The metabolism of Tafenoquine can be increased when combined with Siltuximab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14724</drugbank-id>
      <name>Emapalumab</name>
      <description>The metabolism of Tafenoquine can be increased when combined with Emapalumab.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00122</drugbank-id>
      <name>Choline</name>
      <description>The serum concentration of Choline can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00204</drugbank-id>
      <name>Dofetilide</name>
      <description>The serum concentration of Dofetilide can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00206</drugbank-id>
      <name>Reserpine</name>
      <description>The serum concentration of Reserpine can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00331</drugbank-id>
      <name>Metformin</name>
      <description>The serum concentration of Metformin can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00368</drugbank-id>
      <name>Norepinephrine</name>
      <description>The serum concentration of Norepinephrine can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00413</drugbank-id>
      <name>Pramipexole</name>
      <description>The serum concentration of Pramipexole can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00515</drugbank-id>
      <name>Cisplatin</name>
      <description>The serum concentration of Cisplatin can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00526</drugbank-id>
      <name>Oxaliplatin</name>
      <description>The serum concentration of Oxaliplatin can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00668</drugbank-id>
      <name>Epinephrine</name>
      <description>The serum concentration of Epinephrine can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00709</drugbank-id>
      <name>Lamivudine</name>
      <description>The serum concentration of Lamivudine can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00915</drugbank-id>
      <name>Amantadine</name>
      <description>The serum concentration of Amantadine can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB00988</drugbank-id>
      <name>Dopamine</name>
      <description>The serum concentration of Dopamine can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01043</drugbank-id>
      <name>Memantine</name>
      <description>The serum concentration of Memantine can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB05381</drugbank-id>
      <name>Histamine</name>
      <description>The serum concentration of Histamine can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB06637</drugbank-id>
      <name>Dalfampridine</name>
      <description>The serum concentration of Dalfampridine can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08837</drugbank-id>
      <name>Tetraethylammonium</name>
      <description>The serum concentration of Tetraethylammonium can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08838</drugbank-id>
      <name>Agmatine</name>
      <description>The serum concentration of Agmatine can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB08882</drugbank-id>
      <name>Linagliptin</name>
      <description>The serum concentration of Linagliptin can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB12598</drugbank-id>
      <name>Nafamostat</name>
      <description>The serum concentration of Nafamostat can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB14006</drugbank-id>
      <name>Choline salicylate</name>
      <description>The serum concentration of Choline salicylate can be increased when it is combined with Tafenoquine.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB01175</drugbank-id>
      <name>Escitalopram</name>
      <description>The serum concentration of Tafenoquine can be increased when it is combined with Escitalopram.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB04855</drugbank-id>
      <name>Dronedarone</name>
      <description>The metabolism of Tafenoquine can be decreased when combined with Dronedarone.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB15066</drugbank-id>
      <name>Givosiran</name>
      <description>The serum concentration of Tafenoquine can be increased when it is combined with Givosiran.</description>
    </drug-interaction>
    <drug-interaction>
      <drugbank-id>DB09343</drugbank-id>
      <name>Tipiracil</name>
      <description>The excretion of Tipiracil can be decreased when combined with Tafenoquine.</description>
    </drug-interaction>
  </drug-interactions>
  <calculated-properties>
    <property>
      <kind>logP</kind>
      <value>5.07</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>-5.5</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>Water Solubility</kind>
      <value>1.37e-03 g/l</value>
      <source>ALOGPS</source>
    </property>
    <property>
      <kind>logP</kind>
      <value>4.97</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>IUPAC Name</kind>
      <value>N4-{2,6-dimethoxy-4-methyl-5-[3-(trifluoromethyl)phenoxy]quinolin-8-yl}pentane-1,4-diamine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Traditional IUPAC Name</kind>
      <value>tafenoquine</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Weight</kind>
      <value>463.501</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Monoisotopic Weight</kind>
      <value>463.208276263</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>SMILES</kind>
      <value>COC1=CC(C)=C2C(OC3=CC=CC(=C3)C(F)(F)F)=C(OC)C=C(NC(C)CCCN)C2=N1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Molecular Formula</kind>
      <value>C24H28F3N3O3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChI</kind>
      <value>InChI=1S/C24H28F3N3O3/c1-14-11-20(32-4)30-22-18(29-15(2)7-6-10-28)13-19(31-3)23(21(14)22)33-17-9-5-8-16(12-17)24(25,26)27/h5,8-9,11-13,15,29H,6-7,10,28H2,1-4H3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>InChIKey</kind>
      <value>LBHLFPGPEGDCJG-UHFFFAOYSA-N</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polar Surface Area (PSA)</kind>
      <value>78.63</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Refractivity</kind>
      <value>122.55</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Polarizability</kind>
      <value>47.38</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rotatable Bond Count</kind>
      <value>10</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Acceptor Count</kind>
      <value>5</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>H Bond Donor Count</kind>
      <value>2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest acidic)</kind>
      <value>17.14</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>pKa (strongest basic)</kind>
      <value>10.2</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Physiological Charge</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Number of Rings</kind>
      <value>3</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Bioavailability</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Rule of Five</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>Ghose Filter</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
    <property>
      <kind>MDDR-Like Rule</kind>
      <value>1</value>
      <source>ChemAxon</source>
    </property>
  </calculated-properties>
  <experimental-properties>
    <property>
      <kind>Water Solubility</kind>
      <value>Insoluble</value>
      <source>Melariri P. et al. (2015). Int J Nanomedicine; 10: 1493-1503</source>
    </property>
    <property>
      <kind>logS</kind>
      <value>2.04</value>
      <source>Marella A. et al. (2013). Saudi Pharm J. Jan; 21 (1): 1-12</source>
    </property>
    <property>
      <kind>pKa</kind>
      <value>9.5</value>
      <source>Marella A. et al. (2013). Saudi Pharm J. Jan; 21 (1): 1-12</source>
    </property>
  </experimental-properties>
  <external-identifiers>
    <external-identifier>
      <resource>ChEBI</resource>
      <identifier>141487</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChemSpider</resource>
      <identifier>103196</identifier>
    </external-identifier>
    <external-identifier>
      <resource>PharmGKB</resource>
      <identifier>PA166115580</identifier>
    </external-identifier>
    <external-identifier>
      <resource>Wikipedia</resource>
      <identifier>Tafenoquine</identifier>
    </external-identifier>
    <external-identifier>
      <resource>ChEMBL</resource>
      <identifier>CHEMBL298470</identifier>
    </external-identifier>
  </external-identifiers>
  <external-links/>
  <pathways/>
  <reactions>
    <reaction>
      <sequence>1</sequence>
      <left-element>
        <drugbank-id>DB06608</drugbank-id>
        <name>Tafenoquine</name>
      </left-element>
      <right-element>
        <drugbank-id>DBMET02126</drugbank-id>
        <name>5,6-ortho-quinone</name>
      </right-element>
      <enzymes>
        <enzyme>
          <drugbank-id>BE0002363</drugbank-id>
          <name>Cytochrome P450 2D6</name>
          <uniprot-id>P10635</uniprot-id>
        </enzyme>
      </enzymes>
    </reaction>
  </reactions>
  <snp-effects/>
  <snp-adverse-drug-reactions/>
  <targets/>
  <enzymes>
    <enzyme position="1">
      <id>BE0002363</id>
      <name>Cytochrome P450 2D6</name>
      <organism>Humans</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A35677</ref-id>
            <pubmed-id>27528800</pubmed-id>
            <citation>Ebstie YA, Abay SM, Tadesse WT, Ejigu DA: Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date. Drug Des Devel Ther. 2016 Jul 26;10:2387-99. doi: 10.2147/DDDT.S61443. eCollection 2016.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="P10635" source="Swiss-Prot">
        <name>Cytochrome P450 2D6</name>
        <general-function>Steroid hydroxylase activity</general-function>
        <specific-function>Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.</specific-function>
        <gene-name>CYP2D6</gene-name>
        <locus>22q13.1</locus>
        <cellular-location>Endoplasmic reticulum membrane</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi>7.26</theoretical-pi>
        <molecular-weight>55768.94</molecular-weight>
        <chromosome-location>22</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:2625</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenAtlas</resource>
            <identifier>CYP2D6</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>M20403</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>181350</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1329</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>P10635</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>CP2D6_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.14.14.1</synonym>
          <synonym>Cholesterol 25-hydroxylase</synonym>
          <synonym>CYP2DL1</synonym>
          <synonym>CYPIID6</synonym>
          <synonym>Cytochrome P450-DB1</synonym>
          <synonym>Debrisoquine 4-hydroxylase</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0004641|Cytochrome P450 2D6
MGLEALVPLAVIVAIFLLLVDLMHRRQRWAARYPPGPLPLPGLGNLLHVDFQNTPYCFDQ
LRRRFGDVFSLQLAWTPVVVLNGLAAVREALVTHGEDTADRPPVPITQILGFGPRSQGVF
LARYGPAWREQRRFSVSTLRNLGLGKKSLEQWVTEEAACLCAAFANHSGRPFRPNGLLDK
AVSNVIASLTCGRRFEYDDPRFLRLLDLAQEGLKEESGFLREVLNAVPVLLHIPALAGKV
LRFQKAFLTQLDELLTEHRMTWDPAQPPRDLTEAFLAEMEKAKGNPESSFNDENLRIVVA
DLFSAGMVTTSTTLAWGLLLMILHPDVQRRVQQEIDDVIGQVRRPEMGDQAHMPYTTAVI
HEVQRFGDIVPLGVTHMTSRDIEVQGFRIPKGTTLITNLSSVLKDEAVWEKPFRFHPEHF
LDAQGHFVKPEAFLPFSAGRRACLGEPLARMELFLFFTSLLQHFSFSVPTGQPRPSHHGV
FAFLVSPSPYELCAVPR</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0019275|Cytochrome P450 2D6 (CYP2D6)
ATGGGGCTAGAAGCACTGGTGCCCCTGGCCGTGATAGTGGCCATCTTCCTGCTCCTGGTG
GACCTGATGCACCGGCGCCAACGCTGGGCTGCACGCTACCCACCAGGCCCCCTGCCACTG
CCCGGGCTGGGCAACCTGCTGCATGTGGACTTCCAGAACACACCATACTGCTTCGACCAG
TTGCGGCGCCGCTTCGGGGACGTGTTCAGCCTGCAGCTGGCCTGGACGCCGGTGGTCGTG
CTCAATGGGCTGGCGGCCGTGCGCGAGGCGCTGGTGACCCACGGCGAGGACACCGCCGAC
CGCCCGCCTGTGCCCATCACCCAGATCCTGGGTTTCGGGCCGCGTTCCCAAGGGGTGTTC
CTGGCGCGCTATGGGCCCGCGTGGCGCGAGCAGAGGCGCTTCTCCGTGTCCACCTTGCGC
AACTTGGGCCTGGGCAAGAAGTCGCTGGAGCAGTGGGTGACCGAGGAGGCCGCCTGCCTT
TGTGCCGCCTTCGCCAACCACTCCGGACGCCCCTTTCGCCCCAACGGTCTCTTGGACAAA
GCCGTGAGCAACGTGATCGCCTCCCTCACCTGCGGGCGCCGCTTCGAGTACGACGACCCT
CGCTTCCTCAGGCTGCTGGACCTAGCTCAGGAGGGACTGAAGGAGGAGTCGGGCTTTCTG
CGCGAGGTGCTGAATGCTGTCCCCGTCCTCCTGCATATCCCAGCGCTGGCTGGCAAGGTC
CTACGCTTCCAAAAGGCTTTCCTGACCCAGCTGGATGAGCTGCTAACTGAGCACAGGATG
ACCTGGGACCCAGCCCAGCCCCCCCGAGACCTGACTGAGGCCTTCCTGGCAGAGATGGAG
AAGGCCAAGGGGAACCCTGAGAGCAGCTTCAATGATGAGAACCTGCGCATAGTGGTGGCT
GACCTGTTCTCTGCCGGGATGGTGACCACCTCGACCACGCTGGCCTGGGGCCTCCTGCTC
ATGATCCTACATCCGGATGTGCAGCGCCGTGTCCAACAGGAGATCGACGACGTGATAGGG
CAGGTGCGGCGACCAGAGATGGGTGACCAGGCTCACATGCCCTACACCACTGCCGTGATT
CATGAGGTGCAGCGCTTTGGGGACATCGTCCCCCTGGGTGTGACCCATATGACATCCCGT
GACATCGAAGTACAGGGCTTCCGCATCCCTAAGGGAACGACACTCATCACCAACCTGTCA
TCGGTGCTGAAGGATGAGGCCGTCTGGGAGAAGCCCTTCCGCTTCCACCCCGAACACTTC
CTGGATGCCCAGGGCCACTTTGTGAAGCCGGAGGCCTTCCTGCCTTTCTCAGCAGGCCGC
CGTGCATGCCTCGGGGAGCCCCTGGCCCGCATGGAGCTCTTCCTCTTCTTCACCTCCCTG
CTGCAGCACTTCAGCTTCTCGGTGCCCACTGGACAGCCCCGGCCCAGCCACCATGGTGTC
TTTGCTTTCCTGGTGAGCCCATCCCCCTATGAGCTTTGTGCTGTGCCCCGCTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00067</identifier>
            <name>p450</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>cytoplasm</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>endoplasmic reticulum membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>mitochondrion</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>arachidonic acid epoxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>aromatase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>heme binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>iron ion binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monooxygenase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>oxygen binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>steroid hydroxylase activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>alkaloid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>arachidonic acid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>coumarin metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>exogenous drug catabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>heterocycle metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>isoquinoline alkaloid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>monoterpenoid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>negative regulation of cellular organofluorine metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidative demethylation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>steroid metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>xenobiotic metabolic process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
    <enzyme position="2">
      <id>BE0009560</id>
      <name>Ferredoxin--NADP reductase, apicoplast</name>
      <organism>Plasmodium falciparum (isolate 3D7)</organism>
      <actions>
        <action>substrate</action>
      </actions>
      <references>
        <articles>
          <article>
            <ref-id>A35677</ref-id>
            <pubmed-id>27528800</pubmed-id>
            <citation>Ebstie YA, Abay SM, Tadesse WT, Ejigu DA: Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date. Drug Des Devel Ther. 2016 Jul 26;10:2387-99. doi: 10.2147/DDDT.S61443. eCollection 2016.</citation>
          </article>
        </articles>
        <textbooks/>
        <links/>
        <attachments/>
      </references>
      <known-action>yes</known-action>
      <polypeptide id="C6KT68" source="Swiss-Prot">
        <name>Ferredoxin--NADP reductase, apicoplast</name>
        <general-function/>
        <specific-function>Electron transfer activity</specific-function>
        <gene-name/>
        <locus/>
        <cellular-location>Plastid</cellular-location>
        <transmembrane-regions/>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>43778.59</molecular-weight>
        <chromosome-location/>
        <organism ncbi-taxonomy-id="36329">Plasmodium falciparum (isolate 3D7)</organism>
        <external-identifiers>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>C6KT68</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>FENR_PLAF7</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>1.18.1.2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0051982|Ferredoxin--NADP reductase, apicoplast
MKIRFVFILSVLISGVCCISKNVSRRVANRMTAHSRFLFVHDKYKRNKNFKLKNNKEENN
FINLYTVKNPLKCKIVDKINLVRPNSPNEVYHLEINHNGLFKYLEGHTCGIIPYYNELDN
NPNNQINKDHNIINTTNHTNHNNIALSHIKKQRCARLYSISSSNNMENLSVAIKIHKYEQ
TENAPNITNYGYCSGFIKNLKINDDIYLTGAHGYFNLPNDAIQKNTNFIFIATGTGISPY
ISFLKKLFAYDKNNLYNRNSNYTGYITIYYGVYNEDSILYLNELEYFQKMYPNNINIHYV
FSYKQNSDATSFYVQDEIYKRKTEFLNLFNNYKCELYICGHKSIRYKVMDILKSHDQFDE
KKKKRVHVEVY</amino-acid-sequence>
        <gene-sequence format="FASTA"/>
        <pfams>
          <pfam>
            <identifier>PF00175</identifier>
            <name>NAD_binding_1</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>apicoplast</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>electron transfer activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>FAD binding</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ferredoxin-NAD(P) reductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>ferredoxin-NADP+ reductase activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>identical protein binding</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>oxidation-reduction process</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
      <inhibition-strength/>
      <induction-strength/>
    </enzyme>
  </enzymes>
  <carriers/>
  <transporters>
    <transporter position="3">
      <id>BE0003647</id>
      <name>Solute carrier family 22 member 2</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links>
          <link>
            <ref-id>L3782</ref-id>
            <title>Clinical trials</title>
            <url>https://clinicaltrials.gov/ct2/show/NCT02802501</url>
          </link>
        </links>
        <attachments/>
      </references>
      <known-action>no</known-action>
      <polypeptide id="O15244" source="Swiss-Prot">
        <name>Solute carrier family 22 member 2</name>
        <general-function>Quaternary ammonium group transmembrane transporter activity</general-function>
        <specific-function>Mediates tubular uptake of organic compounds from circulation. Mediates the influx of agmatine, dopamine, noradrenaline (norepinephrine), serotonin, choline, famotidine, ranitidine, histamin, creatinine, amantadine, memantine, acriflavine, 4-[4-(dimethylamino)-styryl]-N-methylpyridinium ASP, amiloride, metformin, N-1-methylnicotinamide (NMN), tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, cisplatin and oxaliplatin. Cisplatin may develop a nephrotoxic action. Transport of creatinine is inhibited by fluoroquinolones such as DX-619 and LVFX. This transporter is a major determinant of the anticancer activity of oxaliplatin and may contribute to antitumor specificity.</specific-function>
        <gene-name>SLC22A2</gene-name>
        <locus>6q26</locus>
        <cellular-location>Membrane</cellular-location>
        <transmembrane-regions>23-43
151-171
178-198
209-229
239-259
264-284
349-369
376-396
415-435
442-462
465-485
495-515</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>8.45</theoretical-pi>
        <molecular-weight>62579.99</molecular-weight>
        <chromosome-location>6</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:10966</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>X98333</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>2281942</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1020</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>O15244</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S22A2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>hOCT2</synonym>
          <synonym>OCT2</synonym>
          <synonym>Organic cation transporter 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0037250|Solute carrier family 22 member 2
MPTTVDDVLEHGGEFHFFQKQMFFLLALLSATFAPIYVGIVFLGFTPDHRCRSPGVAELS
LRCGWSPAEELNYTVPGPGPAGEASPRQCRRYEVDWNQSTFDCVDPLASLDTNRSRLPLG
PCRDGWVYETPGSSIVTEFNLVCANSWMLDLFQSSVNVGFFIGSMSIGYIADRFGRKLCL
LTTVLINAAAGVLMAISPTYTWMLIFRLIQGLVSKAGWLIGYILITEFVGRRYRRTVGIF
YQVAYTVGLLVLAGVAYALPHWRWLQFTVSLPNFFFLLYYWCIPESPRWLISQNKNAEAM
RIIKHIAKKNGKSLPASLQRLRLEEETGKKLNPSFLDLVRTPQIRKHTMILMYNWFTSSV
LYQGLIMHMGLAGDNIYLDFFYSALVEFPAAFMIILTIDRIGRRYPWAASNMVAGAACLA
SVFIPGDLQWLKIIISCLGRMGITMAYEIVCLVNAELYPTFIRNLGVHICSSMCDIGGII
TPFLVYRLTNIWLELPLMVFGVLGLVAGGLVLLLPETKGKALPETIEEAENMQRPRKNKE
KMIYLQVQKLDIPLN</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0012536|Solute carrier family 22 member 2 (SLC22A2)
ATGCCCACCACCGTGGACGATGTCCTGGAGCATGGAGGGGAGTTTCACTTTTTCCAGAAG
CAAATGTTTTTCCTCTTGGCTCTGCTCTCGGCTACCTTCGCGCCCATCTACGTGGGCATC
GTCTTCCTGGGCTTCACCCCTGACCACCGCTGCCGGAGCCCCGGAGTGGCCGAGCTGAGT
CTGCGCTGCGGCTGGAGTCCTGCAGAGGAACTGAACTACACGGTGCCGGGCCCAGGACCT
GCGGGCGAAGCCTCCCCAAGACAGTGTAGGCGCTACGAGGTGGACTGGAACCAGAGCACC
TTCGACTGCGTGGACCCCCTGGCCAGCCTGGACACCAACAGGAGCCGCCTGCCACTGGGC
CCCTGCCGGGACGGCTGGGTGTACGAGACGCCTGGCTCGTCCATCGTCACCGAGTTTAAC
CTGGTATGTGCCAACTCCTGGATGTTGGACCTATTCCAGTCATCAGTGAATGTAGGATTC
TTTATTGGCTCTATGAGTATCGGCTACATAGCAGACAGGTTTGGCCGTAAGCTCTGCCTC
CTAACTACAGTCCTCATAAATGCTGCAGCTGGAGTTCTCATGGCCATTTCCCCAACCTAT
ACGTGGATGTTAATTTTTCGCTTAATCCAAGGACTGGTCAGCAAAGCAGGCTGGTTAATA
GGCTACATCCTGATTACAGAATTTGTTGGGCGGAGATATCGGAGAACAGTGGGGATTTTT
TACCAAGTTGCCTATACAGTTGGGCTCCTGGTGCTAGCTGGGGTGGCTTACGCACTTCCT
CACTGGAGGTGGTTGCAGTTCACAGTTTCTCTGCCCAACTTCTTCTTCTTGCTCTATTAC
TGGTGCATACCTGAGTCTCCCAGGTGGCTGATCTCCCAGAATAAGAATGCTGAAGCCATG
AGAATCATTAAGCACATCGCAAAGAAAAATGGAAAATCTCTACCCGCCTCCCTTCAGCGC
CTGAGACTTGAAGAGGAAACTGGCAAGAAATTGAACCCTTCATTTCTTGACTTGGTCAGA
ACTCCTCAGATAAGGAAACATACTATGATATTGATGTACAACTGGTTCACGAGCTCTGTG
CTCTACCAGGGCCTCATCATGCACATGGGCCTTGCAGGTGACAATATCTACCTGGATTTC
TTCTACTCTGCCCTGGTTGAATTCCCAGCTGCCTTCATGATCATCCTCACCATCGACCGC
ATCGGACGCCGTTACCCTTGGGCTGCATCAAATATGGTTGCAGGGGCAGCCTGTCTGGCC
TCAGTTTTTATACCTGGTGATCTACAATGGCTAAAAATTATTATCTCATGCTTGGGAAGA
ATGGGGATCACAATGGCCTATGAGATAGTCTGCCTGGTCAATGCTGAGCTGTACCCCACA
TTCATTAGGAATCTTGGCGTCCACATCTGTTCCTCAATGTGTGACATTGGTGGCATCATC
ACGCCATTCCTGGTCTACCGGCTCACTAACATCTGGCTTGAGCTCCCGCTGATGGTTTTC
GGCGTGCTTGGCTTGGTTGCTGGAGGTCTGGTGCTGTTGCTTCCAGAAACTAAAGGGAAA
GCTTTGCCTGAGACCATCGAGGAAGCCGAAAATATGCAAAGACCAAGAAAAAATAAAGAA
AAGATGATTTACCTCCAAGTTCAGAAACTAGACATTCCATTGAACTAA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF00083</identifier>
            <name>Sugar_tr</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>extracellular exosome</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>integral component of plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>choline transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>dopamine transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>organic cation transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>quaternary ammonium group transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>ammonium transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>body fluid secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>choline transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>dopamine transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotransmitter biosynthetic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>neurotransmitter secretion</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic cation transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>quaternary ammonium group transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>small molecule metabolic process</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>synaptic transmission</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="4">
      <id>BE0003657</id>
      <name>Multidrug and toxin extrusion protein 1</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments>
          <attachment>
            <ref-id>F1779</ref-id>
            <title>Tafenoquine FDA label</title>
            <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/779/original/Tafenoquine_FDA_label.pdf?1538775503</url>
          </attachment>
        </attachments>
      </references>
      <known-action>no</known-action>
      <polypeptide id="Q96FL8" source="Swiss-Prot">
        <name>Multidrug and toxin extrusion protein 1</name>
        <general-function>Monovalent cation:proton antiporter activity</general-function>
        <specific-function>Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide (NMN), metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfate, acyclovir, ganciclovir and also the zwitterionic cephalosporin, cephalexin and cephradin. Seems to also play a role in the uptake of oxaliplatin (a new platinum anticancer agent). Able to transport paraquat (PQ or N,N-dimethyl-4-4'-bipiridinium); a widely used herbicid. Responsible for the secretion of cationic drugs across the brush border membranes.</specific-function>
        <gene-name>SLC47A1</gene-name>
        <locus>17p11.2</locus>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>38-58
73-93
124-144
153-173
177-197
217-237
257-276
296-316
337-357
371-391
409-429
438-458
547-567</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi>7.62</theoretical-pi>
        <molecular-weight>61921.585</molecular-weight>
        <chromosome-location>17</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:25588</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Gene Database</resource>
            <identifier>AK001709</identifier>
          </external-identifier>
          <external-identifier>
            <resource>GenBank Protein Database</resource>
            <identifier>7023138</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1216</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q96FL8</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S47A1_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>MATE-1</synonym>
          <synonym>MATE1</synonym>
          <synonym>Solute carrier family 47 member 1</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0007028|Multidrug and toxin extrusion protein 1
MEAPEEPAPVRGGPEATLEVRGSRCLRLSAFREELRALLVLAGPAFLVQLMVFLISFISS
VFCGHLGKLELDAVTLAIAVINVTGVSVGFGLSSACDTLISQTYGSQNLKHVGVILQRSA
LVLLLCCFPCWALFLNTQHILLLFRQDPDVSRLTQTYVTIFIPALPATFLYMLQVKYLLN
QGIVLPQIVTGVAANLVNALANYLFLHQLHLGVIGSALANLISQYTLALLLFLYILGKKL
HQATWGGWSLECLQDWASFLRLAIPSMLMLCMEWWAYEVGSFLSGILGMVELGAQSIVYE
LAIIVYMVPAGFSVAASVRVGNALGAGDMEQARKSSTVSLLITVLFAVAFSVLLLSCKDH
VGYIFTTDRDIINLVAQVVPIYAVSHLFEALACTSGGVLRGSGNQKVGAIVNTIGYYVVG
LPIGIALMFATTLGVMGLWSGIIICTVFQAVCFLGFIIQLNWKKACQQAQVHANLKVNNV
PRSGNSALPQDPLHPGCPENLEGILTNDVGKTGEPQSDQQMRQEEPLPEHPQDGAKLSRK
QLVLRRGLLLLGVFLILLVGILVRFYVRIQ</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0017174|Multidrug and toxin extrusion protein 1 (SLC47A1)
ATGGAAGCTCCTGAGGAGCCCGCGCCAGTGCGCGGAGGCCCGGAGGCCACCCTTGAGGTC
CGTGGGTCGCGCTGCTTGCGGCTGTCCGCCTTCCGAGAAGAGCTGCGGGCGCTCTTGGTC
CTGGCTGGCCCCGCGTTCTTGGTTCAGCTGATGGTGTTCCTGATCAGCTTCATAAGCTCC
GTGTTCTGTGGCCACCTGGGCAAGCTGGAGCTGGATGCAGTCACGCTGGCAATCGCGGTT
ATCAATGTCACTGGTGTCTCAGTGGGATTCGGCTTATCTTCTGCCTGTGACACCCTCATC
TCCCAGACGTACGGGAGCCAGAACCTGAAGCACGTGGGCGTGATCCTGCAGCGGAGTGCG
CTCGTCCTGCTCCTCTGCTGCTTCCCCTGCTGGGCGCTCTTTCTCAACACCCAGCACATC
CTGCTGCTCTTCAGGCAGGACCCAGATGTGTCCAGGCTTACCCAGACCTATGTCACGATC
TTCATTCCAGCTCTTCCTGCAACCTTTCTTTATATGTTACAAGTTAAATATTTGCTCAAC
CAGGGAATTGTACTGCCCCAGATCGTAACTGGAGTTGCAGCCAACCTTGTCAATGCCCTC
GCCAACTATCTGTTTCTCCATCAACTGCATCTTGGGGTGATAGGCTCTGCACTGGCAAAC
TTGATTTCCCAGTACACCCTGGCTCTACTCCTCTTTCTCTACATCCTCGGGAAAAAACTG
CATCAAGCTACATGGGGAGGCTGGTCCCTCGAGTGCCTGCAGGACTGGGCCTCCTTCCTC
CGCCTGGCCATCCCCAGCATGCTCATGCTGTGCATGGAGTGGTGGGCCTATGAGGTCGGG
AGCTTCCTCAGTGGCATCCTCGGCATGGTGGAGCTGGGCGCTCAGTCCATCGTGTATGAA
CTGGCCATCATTGTGTACATGGTCCCTGCAGGCTTCAGTGTGGCTGCCAGTGTCCGGGTA
GGAAACGCTCTGGGTGCTGGAGACATGGAGCAGGCACGGAAGTCCTCTACCGTTTCCCTG
CTGATTACAGTGCTCTTTGCTGTAGCCTTCAGTGTCCTGCTGTTAAGCTGTAAGGATCAC
GTGGGGTACATTTTTACTACCGACCGAGACATCATTAATCTGGTGGCTCAGGTGGTTCCA
ATTTATGCTGTTTCCCACCTCTTTGAAGCTCTTGCTTGCACGAGTGGTGGTGTTCTGAGG
GGGAGTGGAAATCAGAAGGTTGGAGCCATTGTGAATACCATTGGGTACTATGTGGTTGGC
CTCCCCATCGGGATCGCGCTGATGTTTGCAACCACACTTGGAGTGATGGGTCTGTGGTCA
GGGATCATCATCTGTACAGTCTTTCAAGCTGTGTGTTTTCTAGGCTTTATTATTCAGCTA
AATTGGAAAAAAGCCTGTCAGCAGGCTCAGGTACACGCCAATTTGAAAGTAAACAACGTG
CCTCGGAGTGGGAATTCTGCTCTCCCTCAGGATCCGCTTCACCCAGGGTGCCCTGAAAAC
CTTGAAGGAATTTTAACGAACGATGTTGGAAAGACAGGCGAGCCTCAGTCAGATCAGCAG
ATGCGCCAAGAAGAACCTTTGCCGGAACATCCACAGGACGGCGCTAAATTGTCCAGGAAA
CAGCTGGTGCTGCGGCGAGGGCTTCTGCTCCTGGGGGTCTTCTTAATCTTGCTGGTGGGG
ATTTTAGTGAGATTCTATGTCAGAATTCAGTGA</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01554</identifier>
            <name>MatE</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>membrane-bounded vesicle</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>monovalent cation</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>organic cation transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
    <transporter position="5">
      <id>BE0004752</id>
      <name>Multidrug and toxin extrusion protein 2</name>
      <organism>Humans</organism>
      <actions>
        <action>inhibitor</action>
      </actions>
      <references>
        <articles/>
        <textbooks/>
        <links/>
        <attachments>
          <attachment>
            <ref-id>F1793</ref-id>
            <title>Tafenoquine FDA label</title>
            <url>//s3-us-west-2.amazonaws.com/drugbank/cite_this/attachments/files/000/001/793/original/Tafenoquine_FDA.pdf?1539104347</url>
          </attachment>
        </attachments>
      </references>
      <known-action>no</known-action>
      <polypeptide id="Q86VL8" source="Swiss-Prot">
        <name>Multidrug and toxin extrusion protein 2</name>
        <general-function>Drug transmembrane transporter activity</general-function>
        <specific-function>Solute transporter for tetraethylammonium (TEA), 1-methyl-4-phenylpyridinium (MPP), cimetidine, N-methylnicotinamide, metformin, creatinine, guanidine, procainamide, topotecan, estrone sulfate, acyclovir, and ganciclovir. Responsible for the secretion of cationic drugs across the brush border membranes.</specific-function>
        <gene-name>SLC47A2</gene-name>
        <locus/>
        <cellular-location>Cell membrane</cellular-location>
        <transmembrane-regions>34-54
67-87
120-140
154-174
220-240
249-269
290-309
328-348
369-389
403-423
443-463
467-487
579-599</transmembrane-regions>
        <signal-regions/>
        <theoretical-pi/>
        <molecular-weight>65083.915</molecular-weight>
        <chromosome-location>17</chromosome-location>
        <organism ncbi-taxonomy-id="9606">Humans</organism>
        <external-identifiers>
          <external-identifier>
            <resource>HUGO Gene Nomenclature Committee (HGNC)</resource>
            <identifier>HGNC:26439</identifier>
          </external-identifier>
          <external-identifier>
            <resource>Guide to Pharmacology</resource>
            <identifier>1217</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProtKB</resource>
            <identifier>Q86VL8</identifier>
          </external-identifier>
          <external-identifier>
            <resource>UniProt Accession</resource>
            <identifier>S47A2_HUMAN</identifier>
          </external-identifier>
        </external-identifiers>
        <synonyms>
          <synonym>Kidney-specific H(+)/organic cation antiporter</synonym>
          <synonym>MATE-2</synonym>
          <synonym>MATE2</synonym>
          <synonym>Solute carrier family 47 member 2</synonym>
        </synonyms>
        <amino-acid-sequence format="FASTA">&gt;lcl|BSEQ0008601|Multidrug and toxin extrusion protein 2
MDSLQDTVALDHGGCCPALSRLVPRGFGTEMWTLFALSGPLFLFQVLTFMIYIVSTVFCG
HLGKVELASVTLAVAFVNVCGVSVGVGLSSACDTLMSQSFGSPNKKHVGVILQRGALVLL
LCCLPCWALFLNTQHILLLFRQDPDVSRLTQDYVMIFIPGLPVIFLYNLLAKYLQNQGWL
KGQEEESPFQTPGLSILHPSHSHLSRASFHLFQKITWPQVLSGVVGNCVNGVANYALVSV
LNLGVRGSAYANIISQFAQTVFLLLYIVLKKLHLETWAGWSSQCLQDWGPFFSLAVPSML
MICVEWWAYEIGSFLMGLLSVVDLSAQAVIYEVATVTYMIPLGLSIGVCVRVGMALGAAD
TVQAKRSAVSGVLSIVGISLVLGTLISILKNQLGHIFTNDEDVIALVSQVLPVYSVFHVF
EAICCVYGGVLRGTGKQAFGAAVNAITYYIIGLPLGILLTFVVRMRIMGLWLGMLACVFL
ATAAFVAYTARLDWKLAAEEAKKHSGRQQQQRAESTATRPGPEKAVLSSVATGSSPGITL
TTYSRSECHVDFFRTPEEAHALSAPTSRLSVKQLVIRRGAALGAASATLMVGLTVRILAT
RH</amino-acid-sequence>
        <gene-sequence format="FASTA">&gt;lcl|BSEQ0021398|Multidrug and toxin extrusion protein 2 (SLC47A2)
ATGGACAGCCTCCAGGACACAGTGGCCCTGGACCATGGGGGCTGCTGCCCTGCCCTCAGC
AGGCTGGTTCCCAGAGGCTTTGGGACTGAGATGTGGACTCTCTTTGCCCTTTCTGGACCC
CTGTTCCTGTTCCAGGTGCTGACTTTTATGATCTACATCGTGAGCACTGTGTTCTGCGGG
CACCTGGGCAAGGTGGAGCTGGCATCGGTGACCCTCGCGGTGGCCTTTGTCAATGTCTGC
GGAGTTTCTGTAGGAGTTGGTTTGTCTTCGGCATGTGACACCTTGATGTCTCAGAGCTTC
GGCAGCCCCAACAAGAAGCACGTGGGCGTGATCCTGCAGCGGGGCGCGCTGGTCCTGCTC
CTCTGCTGCCTCCCTTGCTGGGCGCTCTTCCTCAACACCCAGCACATCCTGCTGCTCTTC
CGGCAGGACCCGGACGTGTCCAGGTTGACCCAGGACTATGTAATGATTTTCATTCCAGGA
CTTCCGGTGATTTTTCTTTACAATCTGCTGGCAAAATATTTGCAAAATCAGAAGATCACC
TGGCCCCAAGTCCTCAGTGGTGTGGTGGGCAACTGTGTCAACGGTGTGGCCAACTATGCC
CTGGTTTCTGTGCTGAACCTGGGGGTCAGGGGCTCCGCCTATGCCAACATCATCTCCCAG
TTTGCACAGACCGTCTTCCTCCTTCTCTACATTGTGCTGAAGAAGCTGCACCTGGAGACG
TGGGCAGGTTGGTCCAGCCAGTGCCTGCAGGACTGGGGCCCCTTCTTCTCCCTGGCTGTC
CCCAGCATGCTCATGATCTGTGTTGAGTGGTGGGCCTATGAGATCGGGAGCTTCCTCATG
GGGCTGCTCAGTGTGGTGGATCTCTCTGCCCAGGCTGTCATCTACGAGGTGGCCACTGTG
ACCTACATGATTCCCTTGGGGCTCAGCATCGGGGTCTGTGTCCGAGTGGGGATGGCTCTG
GGGGCTGCGGATACTGTGCAGGCCAAGCGCTCGGCCGTCTCGGGCGTGCTCAGCATAGTT
GGCATTTCCCTGGTCCTGGGCACCCTGATAAGCATCCTGAAAAATCAGCTGGGGCATATT
TTTACCAATGATGAAGATGTCATTGCCCTGGTGAGCCAGGTCTTGCCGGTTTATAGTGTC
TTTCACGTGTTTGAGGCCATCTGTTGTGTCTATGGCGGAGTTCTGAGAGGAACTGGGAAG
CAGGCCTTTGGTGCCGCTGTGAATGCCATCACATATTACATCATCGGCCTACCACTGGGC
ATCCTTCTGACCTTTGTGGTCAGAATGAGAATCATGGGCCTCTGGCTGGGCATGCTGGCC
TGTGTCTTCCTGGCAACTGCTGCCTTTGTTGCTTATACTGCCCGGCTGGACTGGAAGCTT
GCTGCAGAGGAGGCTAAGAAACATTCAGGCCGGCAGCAGCAGCAGAGAGCAGAGAGCACT
GCAACCAGACCTGGGCCTGAGAAAGCAGTCCTATCTTCAGTGGCTACAGGCAGTTCCCCT
GGCATTACCTTGACAACGTATTCAAGGTCTGAGTGCCACGTGGACTTCTTCAGGACTCCA
GAGGAGGCCCACGCCCTTTCAGCTCCTACCAGCAGACTATCAGTGAAACAGCTGGTCATC
CGCCGTGGGGCTGCTCTGGGGGCGGCGTCAGCCACACTGATGGTGGGGCTCACGGTCAGG
ATCCTAGCCACCAGGCACTAG</gene-sequence>
        <pfams>
          <pfam>
            <identifier>PF01554</identifier>
            <name>MatE</name>
          </pfam>
        </pfams>
        <go-classifiers>
          <go-classifier>
            <category>component</category>
            <description>integral component of membrane</description>
          </go-classifier>
          <go-classifier>
            <category>component</category>
            <description>plasma membrane</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>antiporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>function</category>
            <description>drug transmembrane transporter activity</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>drug transmembrane transport</description>
          </go-classifier>
          <go-classifier>
            <category>process</category>
            <description>transmembrane transport</description>
          </go-classifier>
        </go-classifiers>
      </polypeptide>
    </transporter>
  </transporters>
</drug>